Abcam has extended its range of cancer biomarker antibodies by entering into an agreement with Spring Bioscience, which has produced an array of immunohistochemistry (IHC)-optimized recombinant rabbit monoclonal SP clones. This has enlarged their range of antibodies, with 1,300 more gold standard IHC-suitable antibodies against cancer biomarkers now available.
This new development has numerous advantages, such as:
- The ability to target isolated cancer biomarkers and pathologic markers
- Includes some of the most commonly used SP clone monoclonal rabbit antibodies reported in scientific literature
- Includes antibodies that have been optimized especially for use in IHC experiments
Abcam is a global life sciences company providing highly validated antibodies and other binders and assays to the research and clinical communities to help advance the understanding of biology and causes of disease.
Abcam’s mission is to serve life scientists to help them achieve their mission faster by listening to their needs, continuously innovating and improving and by giving them the tools, data and experience they want. Abcam’s ambition is to become the most influential life science company for researchers worldwide.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.